Schwinn D A, McIntyre R W, Reves J G
Department of Anesthesiology, Duke University Hospital, Durham, North Carolina 27710.
Anesth Analg. 1990 Nov;71(5):451-9. doi: 10.1213/00000539-199011000-00001.
Isoflurane is a potent systemic vasodilator. Because isoflurane vasodilation is clinically significant, we sought to explore whether decreases in systemic vascular resistance caused by isoflurane involve the alpha-adrenergic nervous system in humans. Specifically, we tested the hypothesis that isoflurane systemic vasodilation is mediated via inhibition of vascular alpha 1-adrenergic responsiveness. Phenylephrine pressor dose-response curves were established before anesthesia and during isoflurane/oxygen anesthesia in patients undergoing coronary artery bypass surgery; all patients included in the study (n = 11) demonstrated significant (P = 0.0001) decreases in systemic vascular resistance when isoflurane was given in concentrations adequate to produce a 20% decrease in mean arterial blood pressure. Polynomial regression of the phenylephrine dose-response curve was used to estimate the phenylephrine dose required to increase mean arterial blood pressure 15 mm Hg, designated PD15 mm Hg. Each patient served as his or her own control. Preanesthetic baseline PD15 mm Hg values (115 +/- 23 micrograms [1.4 +/- 0.3 micrograms/kg], mean +/- SEM) were not significantly different from isoflurane PD15 mm Hg values (124 +/- 20 micrograms [1.5 +/- 0.3 micrograms/kg]). End-tidal isoflurane concentration ranged from 0.6%-1.5%; isoflurane PD15 mm Hg was not correlated with end-tidal isoflurane concentration. Patient characteristics and hemodynamics did not affect PD15 mm Hg. These results suggest that isoflurane-induced systemic vasodilation is not mediated via inhibition of alpha 1-adrenergic responsiveness, disproving our hypothesis. This finding has clinical importance because it demonstrates that alpha 1-adrenergic stimulation with phenylephrine is effective in correcting hypotension in patients receiving isoflurane anesthesia.
异氟烷是一种强效的全身血管扩张剂。由于异氟烷引起的血管扩张具有临床意义,我们试图探究异氟烷导致的全身血管阻力降低是否涉及人体的α-肾上腺素能神经系统。具体而言,我们检验了以下假设:异氟烷的全身血管扩张是通过抑制血管α1-肾上腺素能反应性介导的。在接受冠状动脉搭桥手术的患者中,于麻醉前及异氟烷/氧气麻醉期间建立去氧肾上腺素升压剂量-反应曲线;纳入研究的所有患者(n = 11)在给予足以使平均动脉血压降低20%的异氟烷浓度时,均表现出全身血管阻力显著降低(P = 0.0001)。采用去氧肾上腺素剂量-反应曲线的多项式回归来估算使平均动脉血压升高15 mmHg所需的去氧肾上腺素剂量,即PD15 mmHg。每位患者均作为自身对照。麻醉前基线PD15 mmHg值(115 ± 23微克[1.4 ± 0.3微克/千克],平均值 ± 标准误)与异氟烷PD15 mmHg值(124 ± 20微克[1.5 ± 0.3微克/千克])无显著差异。呼气末异氟烷浓度范围为0.6% - 1.5%;异氟烷PD15 mmHg与呼气末异氟烷浓度无相关性。患者特征和血流动力学并未影响PD15 mmHg。这些结果表明,异氟烷诱导的全身血管扩张并非通过抑制α1-肾上腺素能反应性介导,这一结果推翻了我们的假设。这一发现具有临床重要性,因为它表明用去氧肾上腺素进行α1-肾上腺素能刺激可有效纠正接受异氟烷麻醉患者的低血压。